Eptinezumab
- Generic Name
- Eptinezumab
- Brand Names
- Vyepti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1644539-04-7
- Unique Ingredient Identifier
- 8202AY8I7H
- Background
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). It was approved by the FDA in February 2020 for the preventive treatment of migrain...
- Indication
Eptinezumab is indicated for the preventive treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath